Sugi Predict

Sugi Predict / Compounds / SCHEMBL10903345

SCHEMBL10903345

SCHEMBL10903345

CC1(N)C=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(=O)N1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDA P32320 6/20 0.42
▸ SLC28A1 O00337 1/20 0.42
▸ SLC28A2 O43868 1/20 0.42
▸ SLC29A1 Q99808 1/20 0.42
▸ SLC28A3 Q9HAS3 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ MTOR P42345 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ THRB P10828 1/20 0.41
▸ MDM2 Q00987 1/20 0.41
▸ NCOA1 Q15788 1/20 0.41
▸ NCOA3 Q9Y6Q9 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ GMNN O75496 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ DNMT1 P26358 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17460347 0.87 MEN1 (0.34) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL3630509 0.87 LMNA (0.45) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL6906558 0.87 LMNA (0.45) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL25188377 0.86 CDA (0.43) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL29845228 0.85 CDA (0.41) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL4751008 0.85 LMNA (0.42) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL31436719 0.85 CDA (0.42) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL65271 0.84 CDA (0.40) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL21357702 0.84 CDA (0.40) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL10903321 0.83 CDA (0.39) CDASLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 — — EP disclosed
WO-2026104647-A1 VACCINE ASTRAZENECA AB (SE) 2026-05-21 — — WO disclosed
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 — — WO disclosed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 — — US disclosed
CN-122060818-A Chemically modified circular RNA molecules, methods of making and uses thereof 上海元码智药生物技术有限公司 2026-05-19 — — CN disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 — — US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 — — US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 — — US disclosed
EP-4727955-A1 CYSTEINE-SUBSTITUTED RSV-F PROTEINS GlaxoSmithKline Biologicals S.A. (BE) 2026-04-22 — — EP disclosed
WO-2015085318-A2 TARGETED ADAPTIVE VACCINES MODERNA THERAPEUTICS, INC. (US) 2015-06-11 — — WO disclosed
WO-2015058069-A1 COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS MODERNA THERAPEUTICS, INC. (US) 2015-04-23 — — WO disclosed
WO-2015051214-A1 POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR MODERNA THERAPEUTICS, INC. (US) 2015-04-09 — — WO disclosed
WO-2015048744-A2 POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES MODERNA THERAPEUTICS, INC. (US) 2015-04-02 — — WO disclosed
WO-2015038892-A1 POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS MODERNA THERAPEUTICS, INC. (US) 2015-03-19 — — WO disclosed
WO-2015034928-A1 CHIMERIC POLYNUCLEOTIDES MODERNA THERAPEUTICS, INC. (US) 2015-03-12 — — WO disclosed
CN-101815521-B Novel siRNA structures QUARK PHARMACEUTICALS INC 2014-12-10 — — CN disclosed
CN-103898110-A NOVEL SIRNA STRUCTURES QUARK PHARMACEUTICALS INC 2014-07-02 — — CN disclosed
CN-101252839-A Novel 2 '-C-methyl and 4' -C-methyl nucleoside derivatives MERCK & CO INC (US) 2008-08-27 — — CN disclosed
US-4587044-A Linkage of proteins to nucleic acids THE JOHNS HOPKINS UNIVERSITY (US) 1986-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS RNGTT, CDA, DCTD CDA 2/4885SLC28A1 1043/4885SLC28A2 856/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 CDA 170/4885SLC28A1 610/4885SLC28A2 670/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 CDA 859/4885SLC28A1 775/4885SLC28A2 1028/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT CDA 942/4885SLC28A1 1985/4885SLC28A2 1854/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 CDA 674/4885SLC28A1 926/4885SLC28A2 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback